
TMDX Stock Forecast & Price Target
TMDX Analyst Ratings
Bulls say
TransMedics Group is rapidly establishing itself as a unique growth story driven by its disruptive Organ Care System (OCS) technology, which addresses the limitations of cold storage and increases the supply of viable organs for transplant. The company's progress in the development and commercialization of OCS Kidney, as well as its plans to use Controlled Hypothermic Organ Preservation System (CHOPS) in its lung and heart transplant trials, positions it as a market leader for years to come. Factors such as new product launches, international growth, and operating margin improvement also contribute to a positive outlook.
Bears say
TransMedics Group is facing challenges with its operating margin and revenue growth, with both metrics declining in the first quarter of 2026. Additionally, management has lowered its price target and expressed concerns about enrollment in its clinical trials. It also faces risks from increasing competition and reimbursement changes. These factors contribute to a negative outlook for TransMedics Group's stock.
This aggregate rating is based on analysts' research of Transmedics Group Inc and is not a guaranteed prediction by Public.com or investment advice.
TMDX Analyst Forecast & Price Prediction
Start investing in TMDX
Order type
Buy in
Order amount
Est. shares
0 shares